InvestorsObserver
×
News Home

Will eFFECTOR Therapeutics Inc (EFTR) Beat the Rest of the Stocks in the Healthcare Sector?

Tuesday, June 06, 2023 10:39 AM | InvestorsObserver Analysts

Mentioned in this article

Will eFFECTOR Therapeutics Inc (EFTR) Beat the Rest of the Stocks in the Healthcare Sector?

eFFECTOR Therapeutics Inc (EFTR) is near the top in its sector according to InvestorsObserver. EFTR gets an overall rating of 71. That means it scores higher than 71% of stocks. eFFECTOR Therapeutics Inc gets a 95 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors.

Overall Score - 71
EFTR has an Overall Score of 71. Find out what this means to you and get the rest of the rankings on EFTR!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 71 means the stock is more attractive than 71 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With eFFECTOR Therapeutics Inc Stock Today?

eFFECTOR Therapeutics Inc (EFTR) stock is trading at $1.09 as of 10:38 AM on Tuesday, Jun 6, a gain of $0.08, or 7.43% from the previous closing price of $1.01. The stock has traded between $1.02 and $1.09 so far today. Volume today is light. So far 452,105 shares have traded compared to average volume of 2,681,153 shares. Click Here to get the full Stock Report for eFFECTOR Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App